New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Heatwurx Inc.

PCSA

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

1.67 0.03 −1.76%
Market cap
$4.8M
P/E
n/m
Fwd P/E FY16e
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
0.4×
Payout ratio
—

Where the cash went Fiscal 2025, year to 31 December 2025

Free cash flow was −$11.4M: capital expenditures were more than operating cash flow. Cash rose by $4.3M. What is a cash flow statement?

Free cash flow
−$11.4M
Returned to shareholders
$0.00
Debt, net
−$6.6K repaid
Change in cash
+$4.3M over the period
Where the cash went, in millions of dollars
Operating cash flow−11.4
Free cash flow−11.4
Shares issued, net+16.6
Other−0.9
Change in cash4.3
Operating cash flowCapexFree cash flow
Operating cash flow, capex and free cash flow, four years
FY16FY17FY23FY24
Operating cash flow−$2.2M−$1.7M−$8.1M−$11M
Capex$0$0$0$0
Free cash flow−$2.2M−$1.7M−$8.1M−$11M

Figures in millions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Net Income
(13.56) (11.85) (11.12) (27.42) (11.43) (14.41) (3.36) (3.76) (1.86) (1.92)
Depreciation & Amortization
0.00 0.00 0.00 0.90 0.79 0.80 0.81 0.01 0.03 0.00
Non Cash Items (Other)
0.63 0.72 2.45 16.37 3.10 10.61 (0.02) (0.14) 0.02 —
Accounts Payable Change
0.18 0.57 (0.02) 0.11 (0.10) 0.25 (0.22) 0.24 0.01 0.00
Change in other assets and liabilities
1.37 (0.68) 0.62 0.44 (1.08) (0.39) 0.04 (0.05) 0.15 (0.24)
Operating Cash Flow
(11.39) (11.24) (8.06) (9.61) (8.72) (3.14) (2.75) (3.71) (1.65) (2.15)
Capital expenditures
— 0.00 0.00 — — — — — (0.02) (0.02)
Change in intangibles (net)
(0.85) — — — — — — (0.02) — —
Net Aquisitions
— — — — — — — — 0.01 —
Short Term Investments Change (Net)
— — — — — — — — 1.02 (1.02)
Investing cash flow
(0.85) 0.00 0.00 — — — — (0.02) 1.01 (1.04)
Repayment/Issuance of Debt (Net)
(0.01) (0.01) — (0.09) (0.09) 0.86 0.81 — 2.58 —
Equity Repurchase (Common, Net)
16.60 7.76 6.32 (0.30) 10.05 17.10 — 2.87 — 4.27
Other financial activities
(0.01) (0.02) (0.05) (0.09) (0.25) (0.10) 0.90 (0.25) (0.15) —
Financing cash flow
16.58 7.73 6.27 (0.39) 9.80 17.87 1.70 2.62 2.43 4.27
Change in Cash
4.35 (3.51) (1.80) (9.99) 1.08 14.72 (1.05) (1.11) 1.78 1.07
Beginning Cash
1.19 4.71 6.50 16.50 15.42 0.69 1.74 2.85 1.07 —
Ending Cash
5.54 1.19 4.71 6.50 16.50 15.42 0.69 1.74 2.85 1.07
Stock Based Compensation
0.86 0.63 1.06 8.83 3.41 2.73 0.51 0.07 — —
Dividends Paid (Common)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
1.54 (0.11) 0.61 0.54 (1.18) (0.14) (0.18) 0.19 0.16 (0.24)
Investments Change (Net)
— — — — — — — — 1.02 (1.02)
Issuance/Purchase of Shares
16.60 7.76 6.32 (0.30) 10.05 17.10 — 2.87 — 4.27
Other line items
Revenue per Employee
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 18 Nov 2026